DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ABLAVAR
All Clinical Trials for ABLAVAR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00375830 | Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases | Completed | Stanford University | Phase 2 | 2006-01-01 | This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. |
| NCT01135316 | Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR | Completed | Lantheus Medical Imaging | N/A | 2009-10-01 | Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months. |
| NCT01165892 | Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) | Completed | Lantheus Medical Imaging | N/A | 2011-07-01 | The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI). |
| NCT01165892 | Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) | Completed | Washington University School of Medicine | N/A | 2011-07-01 | The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI). |
| NCT01431300 | Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants | Completed | Lantheus Medical Imaging | N/A | 2011-08-01 | The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images. |
| NCT01431300 | Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants | Completed | Duke University | N/A | 2011-08-01 | The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images. |
| NCT01609920 | Nodal Staging in Breast Cancer With MRL | Terminated | Maastricht University Medical Center | N/A | 2012-05-01 | The aim of this study is to examine the diagnostic performance of gadofosveset enhanced magnetic resonance imaging lymphography (MRL). The diagnostic performance of MRL will be determined on the basis of a node-to-node matching of imaged nodes to the definitive histopathology. The pathologic examination of the sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) will be regarded as the golden standard for nodal involvement. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ABLAVAR
Condition Name
Clinical Trial Locations for ABLAVAR
Trials by Country
Clinical Trial Progress for ABLAVAR
Clinical Trial Phase
Clinical Trial Sponsors for ABLAVAR
Sponsor Name
